Bhargava Kandala, PhD

Merck & Co., Inc.

Disclosure(s): Merck & Co.: Employment, Stocks/Bonds (Public Company)

Poster(s):

• (P-344) Modeling Confirms Islatravir 0.25 mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4+ T-cell Counts in People Living with HIV
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-1245) An Open-Label Phase 1 Study to Evaluate the Effect of Multiple Doses of Rifabutin on the Single-Dose Pharmacokinetics of Ulonivirine in Adults without HIV
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET